89Zr标记抗PD-L1抗体PET监测吉西他滨治疗诱导的肿瘤PD-L1表达调节
研究开发了89Zr标记的抗PD-L1免疫PET,用于在活体内监测化疗介导的肿瘤PD-L1表达变化。小鼠模型中,吉西他滨治疗上调了肿瘤PD-L1表达,并显著增加了89Zr-抗PD-L1的肿瘤摄取,提示该PET方法可用于监测化疗介导的肿瘤PD-L1调节。
要点
- 89Zr-抗PD-L1合成简便高效,具有良好靶向特异性和成像特性。
- 吉西他滨处理CT26细胞24小时使PD-L1蛋白增至对照的592.4%±114.2%。
- 吉西他滨治疗使荷瘤小鼠肿瘤摄取从1.56%±0.48%增至6.24%±0.37%ID/g。
核心结论
- 89Zr-抗PD-L1具有特异性靶向和良好成像特性,可用于监测化疗介导的肿瘤PD-L1调节。
研究设计与样本
- 研究在小鼠中进行,评估89Zr-抗PD-L1的药代动力学、生物分布和PET成像,并比较CT26与PD-L1过表达CT26/PD-L1细胞。
主要发现
- CT26/PD-L1细胞对89Zr-抗PD-L1的结合比弱表达CT26细胞高102.2±6.7倍。
- 吉西他滨处理CT26细胞24小时使PD-L1蛋白增至对照的592.4%±114.2%,并增加89Zr-抗PD-L1结合。
- 荷瘤小鼠中吉西他滨使肿瘤摄取从1.56%±0.48%升至6.24%±0.37%ID/g,肿瘤/血比为34.7。
临床怎么用
- 该PET方法有望用于活体内监测化疗后肿瘤PD-L1表达变化,辅助免疫治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We developed an 89Zr-labeled anti-programmed death ligand 1 (anti-PD-L1) immune PET that can monitor chemotherapy-mediated modulation of tumor PD-L1 expression in living subjects. Methods: Anti-PD-L1 underwent sulfohydryl moiety-specific conjugation with maleimide-deferoxamine followed by 89Zr radiolabeling. CT26 colon cancer cells and PD-L1-overexpressing CT26/PD-L1 cells underwent binding assays, flow cytometry, and Western blotting. In vivo pharmacokinetics, biodistribution, and PET imaging were evaluated in mice. Results:89Zr-anti-PD-L1 synthesis was straightforward and efficient. Sodium dodecyl sulfate polyacrylamide gel electrophoresis showed that reduction produced half-antibody fragments, and matrix-assisted laser desorption ionization time-of-flight analysis estimated 2.18 conjugations per antibody, indicating specific conjugation at the hinge-region disulfide bonds. CT26/PD-L1 cells showed 102.2 ± 6.7-fold greater 89Zr-anti-PD-L1 binding than that of weakly expressing CT26 cells. Excellent target specificity was confirmed by a drastic reduction in binding by excess cold antibody. Intravenous 89Zr-anti-PD-L1 followed biexponential blood clearance. PET/CT image analysis demonstrated decreases in major organ activity over 7 d, whereas high CT26/PD-L1 tumor activity was maintained. Again, this was suppressed by excess cold antibody. Treatment of CT26 cells with gemcitabine for 24 h augmented PD-L1 protein to 592.4% ± 114.2% of the control level and increased 89Zr-anti-PD-L1 binding, accompanied by increased AKT (protein kinase B) activation and reduced phosphatase and tensin homolog (PTEN). In CT26 tumor-bearing mice, gemcitabine treatment substantially increased tumor uptake from 1.56% ± 0.48% to 6.24% ± 0.37% injected dose per gram (tumor-to-blood ratio, 34.7). Immunoblots revealed significant increases in tumor PD-L1 and activated AKT and a decrease in PTEN. Conclusion:89Zr-anti-PD-L1 showed specific targeting with favorable imaging properties. Gemcitabine treatment upregulated cancer cell and tumor PD-L1 expression and increased 89Zr-anti-PD-L1 uptake. 89Zr-anti-PD-L1 PET may thus be useful for monitoring chemotherapy-mediated tumor PD-L1 modulation in living subjects.
引用
- Jung KH, Park JW, Lee JH, et al. 89Zr-Labeled Anti-PD-L1 Antibody PET Monitors Gemcitabine Therapy-Induced Modulation of Tumor PD-L1 Expression. J Nucl Med. 2020. PMID: 32917780. doi:10.2967/jnumed.120.250720
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。